We are international
• treatment options TEXT SIZE   
supportive care    back

ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A.

To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

 related articles